Last week saw Deloitte publish it’s fourth annual report looking at the return on investment pharmaceutical companies are seeing in their research and development projects.
The report, co-produced with Thomson Reuters, looks at the current state of development pipelines in 12 top life science companies, and calculates a projected financial return for their products in the late stages of the pipeline.
To see what the report suggests will help to pull pharma out of this decline in value ofÂ R&D investments why not have a read of our post on what pharma companies should take away from the report.
This infographic looks at just a few of the take-away statistics from the report:
See the original infographic here.